Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.3% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 101,462 shares of the medical research company’s stock after selling 4,599 shares during the quarter. Anchor Capital Advisors LLC’s holdings in Charles River Laboratories International were worth $20,960,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Acadian Asset Management LLC bought a new position in shares of Charles River Laboratories International in the second quarter valued at approximately $110,000. MainStreet Investment Advisors LLC bought a new position in Charles River Laboratories International during the 2nd quarter valued at $418,000. Advisor OS LLC increased its position in shares of Charles River Laboratories International by 15.4% during the 2nd quarter. Advisor OS LLC now owns 16,564 shares of the medical research company’s stock valued at $3,422,000 after purchasing an additional 2,207 shares during the period. Victory Capital Management Inc. raised its stake in shares of Charles River Laboratories International by 1.3% in the 2nd quarter. Victory Capital Management Inc. now owns 465,694 shares of the medical research company’s stock worth $96,203,000 after buying an additional 5,876 shares in the last quarter. Finally, Mesirow Institutional Investment Management Inc. acquired a new stake in shares of Charles River Laboratories International in the second quarter valued at $2,825,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CRL. The Goldman Sachs Group lowered their target price on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Argus reissued a “hold” rating on shares of Charles River Laboratories International in a research note on Friday, June 28th. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $270.00 to $205.00 in a research report on Thursday, August 8th. UBS Group dropped their price target on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Finally, Evercore ISI dropped their target price on shares of Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Ten investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $231.00.

Charles River Laboratories International Trading Down 1.7 %

Shares of NYSE CRL opened at $187.96 on Friday. The stock has a market cap of $9.68 billion, a price-to-earnings ratio of 22.11, a PEG ratio of 3.97 and a beta of 1.36. The business has a 50 day simple moving average of $210.24 and a 200 day simple moving average of $227.56. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.21 and a current ratio of 1.58. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 7th. The medical research company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.39 by $0.41. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. On average, research analysts predict that Charles River Laboratories International, Inc. will post 10.02 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its board has authorized a stock buyback plan on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).